1.Construction and expression of an anti-EGFR/anti-KDR bispecific single-chain diabody.
Ya-qiong ZHOU ; Juan ZHANG ; Hai-zhen JIN ; Yuan HE ; Tong WANG ; Min WANG
Acta Pharmaceutica Sinica 2012;47(10):1317-1322
Bispecific antibodies have been exploited as both cancer immunodiagnostics and cancer therapeutics, which have shown promises in clinical trials in cancer imaging and therapy. To improve the anti-tumor effect, an scDb (bispecific single-chain diabody) was constructed from the variable domain genes of two scFvs (single-chain variable fragment antibodies) directed against human EGFR (epidermal growth factor receptor) and VEGFR2 (vascular endothelial growth factor receptor 2) extracellular domains. The anti-EGFR/ anti-KDR scDb was constructed into pHEN2 plasmid and expressed in Escherichia coli HB2151 host. After purification by one-step affinity chromatography of IMAC, scDb protein was characterized by Western blotting. The yield of scDb protein was 570 microg per liter medium. scDb bound to EGFR as efficiently as the parental antibody scFv-E10, while a little bit weaker than the parental antibody scFv-AK404R when bound to KDR. In conclusion, the scDb protein could bind both EGFR and KDR specifically and could be applied for further anti-tumor research.
Antibodies, Bispecific
;
biosynthesis
;
genetics
;
Escherichia coli
;
metabolism
;
Humans
;
Plasmids
;
Protein Binding
;
Receptor, Epidermal Growth Factor
;
immunology
;
Single-Chain Antibodies
;
biosynthesis
;
genetics
;
Vascular Endothelial Growth Factor Receptor-2
;
immunology
2.Next generation of antibody therapy for cancer.
Chinese Journal of Cancer 2011;30(5):293-302
Monoclonal antibodies (mAbs) have become a major class of therapeutic agents providing effective alternatives to treating various human diseases. To date, 15 mAbs have been approved by regulatory agencies in the world for clinical use in oncology indications. The selectivity and specificity, the unique pharmacokinetics, and the ability to engage and activate the host immune system differentiate these biologics from traditional small molecule anticancer drugs. mAb-based regimens have brought clinical benefits, including improvements in overall survival, to patients with a variety of cancers. Many challenges still remain, however, to fully realize the potential of these new medicines. With our further understanding of cancer biology, mechanism of antibody action, and advancement of antibody engineering technologies, many novel antibody formats or antibody-derived molecules are emerging as promising new generation therapeutics. Carefully designed and engineered, they retain the advantage of specificity and selectivity of original antibodies, but in the meantime acquire additional special features such as improved pharmacokinetics, increased selectivity, and enhanced anticancer efficacy. Promising clinical results are being generated with these newly improved antibody-based therapeutics.
Antibodies, Monoclonal
;
therapeutic use
;
Antibodies, Monoclonal, Humanized
;
therapeutic use
;
Antigens, CD20
;
immunology
;
Humans
;
Immunoconjugates
;
therapeutic use
;
Neoplasms
;
drug therapy
;
immunology
;
Protein Engineering
;
RANK Ligand
;
immunology
;
Receptor, Epidermal Growth Factor
;
immunology
;
Receptor, ErbB-2
;
immunology
;
Vascular Endothelial Growth Factor A
;
immunology
3.BRAF V600E mutation as a predictive factor of anti-EGFR monoclonal antibodies therapeutic effects in metastatic colorectal cancer: a meta-analysis.
Qi WANG ; Wei-guo HU ; Qi-bin SONG ; Jia WEI
Chinese Medical Sciences Journal 2014;29(4):197-203
OBJECTIVETo investigate the correlation between BRAF V600E mutation and anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (MoAbs) therapeutic effects in metastatic colorectal cancer.
METHODSStudies were included into meta-analysis to investigate the association between BRAF V600E mutation and clinical outcome in metastatic colorectal cancer patients treated with anti-EGFR MoAbs.
RESULTSA total of 7 studies were included in this meta-analysis. The 7 studies included 1352 patients in total, sample sizes ranged from 67 to 493. Objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) were collected from included studies and were used to assess the strength of the relation. In patients with wild-type KRAS, the pooled odds ratio for ORR of mutant BRAF over wild-type BRAF was 0.27 (95% CI=0.10-0.70). BRAF mutation predicted a deterioration in PFS and OS in wild-type KRAS patients treated with anti-EGFR MoAbs (hazard ratio=2.78, 95% CI=1.62-4.76; hazard ratio=2.54, 95% CI=1.93-3.32).
CONCLUSIONBRAF V600E mutation is related to lack of response and worse survival in wild-type KRAS metastatic colorectal cancer patients treated with anti-EGFR MoAbs.
Antibodies, Monoclonal ; immunology ; Colorectal Neoplasms ; immunology ; pathology ; Humans ; Mutation ; Neoplasm Metastasis ; immunology ; Proto-Oncogene Proteins B-raf ; genetics ; Receptor, Epidermal Growth Factor ; immunology
5.One target, different effects: a comparison of distinct therapeutic antibodies against the same targets.
Experimental & Molecular Medicine 2011;43(10):539-549
To date, more than 30 antibodies have been approved worldwide for therapeutic use. While the monoclonal antibody market is rapidly growing, the clinical use of therapeutic antibodies is mostly limited to treatment of cancers and immunological disorders. Moreover, antibodies against only five targets (TNF-alpha, HER2, CD20, EGFR, and VEGF) account for more than 80 percent of the worldwide market of therapeutic antibodies. The shortage of novel, clinically proven targets has resulted in the development of many distinct therapeutic antibodies against a small number of proven targets, based on the premise that different antibody molecules against the same target antigen have distinct biological and clinical effects from one another. For example, four antibodies against TNF-alpha have been approved by the FDA -- infliximab, adalimumab, golimumab, and certolizumab pegol -- with many more in clinical and preclinical development. The situation is similar for HER2, CD20, EGFR, and VEGF, each having one or more approved antibodies and many more under development. This review discusses the different binding characteristics, mechanisms of action, and biological and clinical activities of multiple monoclonal antibodies against TNF-alpha, HER-2, CD20, and EGFR and provides insights into the development of therapeutic antibodies.
Animals
;
Antibodies, Monoclonal/*pharmacology/therapeutic use
;
Antigens, CD20/immunology
;
Drug Discovery
;
Humans
;
Immune System Diseases/*drug therapy/immunology
;
*Immunotherapy/trends
;
*Molecular Targeted Therapy
;
Neoplasms/*drug therapy/immunology
;
Receptor, Epidermal Growth Factor/immunology
;
Receptor, erbB-2/immunology
;
Tumor Necrosis Factor-alpha/immunology
;
United States
;
United States Food and Drug Administration
;
Vascular Endothelial Growth Factor A/immunology
6.One target, different effects: a comparison of distinct therapeutic antibodies against the same targets.
Experimental & Molecular Medicine 2011;43(10):539-549
To date, more than 30 antibodies have been approved worldwide for therapeutic use. While the monoclonal antibody market is rapidly growing, the clinical use of therapeutic antibodies is mostly limited to treatment of cancers and immunological disorders. Moreover, antibodies against only five targets (TNF-alpha, HER2, CD20, EGFR, and VEGF) account for more than 80 percent of the worldwide market of therapeutic antibodies. The shortage of novel, clinically proven targets has resulted in the development of many distinct therapeutic antibodies against a small number of proven targets, based on the premise that different antibody molecules against the same target antigen have distinct biological and clinical effects from one another. For example, four antibodies against TNF-alpha have been approved by the FDA -- infliximab, adalimumab, golimumab, and certolizumab pegol -- with many more in clinical and preclinical development. The situation is similar for HER2, CD20, EGFR, and VEGF, each having one or more approved antibodies and many more under development. This review discusses the different binding characteristics, mechanisms of action, and biological and clinical activities of multiple monoclonal antibodies against TNF-alpha, HER-2, CD20, and EGFR and provides insights into the development of therapeutic antibodies.
Animals
;
Antibodies, Monoclonal/*pharmacology/therapeutic use
;
Antigens, CD20/immunology
;
Drug Discovery
;
Humans
;
Immune System Diseases/*drug therapy/immunology
;
*Immunotherapy/trends
;
*Molecular Targeted Therapy
;
Neoplasms/*drug therapy/immunology
;
Receptor, Epidermal Growth Factor/immunology
;
Receptor, erbB-2/immunology
;
Tumor Necrosis Factor-alpha/immunology
;
United States
;
United States Food and Drug Administration
;
Vascular Endothelial Growth Factor A/immunology
7.Performance Evaluation of ADVIA Centaur XPT.
Eun Jung CHO ; Kyoung Jin PARK ; Woochang LEE ; Sail CHUN ; Won Ki MIN
Journal of Laboratory Medicine and Quality Assurance 2017;39(1):47-51
We have evaluated the performance of a recently developed immunoassay analyzer, ADVIA Centaur XPT (Siemens, Germany). Precision, linearity, and comparison studies were performed according to the CLSI guidelines. The test items evaluated were ferritin, folate, human epidermal growth factor receptor 2/neu, homocysteine, vitamin B₁₂, B-type natriuretic peptide, creatine kinase–myocardial band, myoglobin, procalcitonin, troponin I. Bio-Rad control materials, linearity materials, and patients' samples were used for the evaluation. For the correlation study, ADVIA Centaur XP (Siemens) were used as comparative methods. The total coefficients of variations (CVs) of the analytes were between 2.5% and 7.0%. The results of linearity evaluation were also acceptable for the range tested. Correlations with comparative methods were good. The overall analytical performance of ADVIA Centaur XPT is acceptable for the immunology analyzer. Therefore, ADVIA Centaur XPT is expected to be widely used.
Allergy and Immunology
;
Creatine
;
Ferritins
;
Folic Acid
;
Homocysteine
;
Humans
;
Immunoassay
;
Myoglobin
;
Natriuretic Peptide, Brain
;
Receptor, Epidermal Growth Factor
;
Statistics as Topic
;
Troponin I
;
Vitamins
8.Biotherapy of cancer by anti-EGFR monoclonal antibody.
Jing WANG ; Zhi-Yun MENG ; Sou-Ting FU ; Gui-Fang DOU
Journal of Experimental Hematology 2007;15(5):1135-1138
Epidermal growth factor receptor (EGFR) is mutated, dysregulated or overexpressed in many epithelial malignancies, and EGFR activation has been found to be important in tumor growth and progression. Anti-EGFR monoclonal antibodies target the extracellular domain of EGFR; and show promising anti-tumor potential at clinical trials without severe side effects. In this article the pharmacokenetics and clinical study of 3 anti-EGFR monoclonal antibodies (cetuximab, panitumumab and nimotuzomab) were reviewed.
Antibodies, Monoclonal
;
pharmacokinetics
;
therapeutic use
;
Antibodies, Monoclonal, Humanized
;
Antineoplastic Agents
;
therapeutic use
;
Cetuximab
;
Humans
;
Neoplasms
;
therapy
;
Receptor, Epidermal Growth Factor
;
antagonists & inhibitors
;
immunology
9.Design and activity analysis of chimeric epidermal growth factor fusion vaccine E5T-mSEA.
Qingqing YIN ; Haiwei JIA ; Yanhong ZHANG ; Chuanxuan LIU ; Qingjun MA ; Buchang ZHANG ; Hui ZHONG ; Quanbin XU
Chinese Journal of Biotechnology 2010;26(3):357-362
Epidermal growth factor receptor (EGFR) and its ligands (EGF and TGFalpha) are over-expressed in a variety of tumors. Immunization EGF-carrier protein inhibits tumor growth through abrogating binding of EGF to EGFR. Here, a chimeric protein of EGF and TGFalpha (E5T) was genetically fused to Staphylococcal enterotoxin A (SEA), a bacterial superantigenic protein which promotes humoral B cell response through enhancement of Ag-specific CD4 T cells activity. The resulted fusion proteins were expressed in Escherichia coli and purified though metal chelating affinity chromatography. Immunization of E5T-mSEA fusion protein in mice induced production of high titers antibodies, which recognize both EGF and TGFalpha. Anti- E5T-mSEA serum at dilution of 1:10 significantly inhibited growth of A431 cell lines but had little effect on 293T cell lines.
Amino Acid Sequence
;
Animals
;
Cancer Vaccines
;
biosynthesis
;
immunology
;
Cell Line, Tumor
;
Enterotoxins
;
biosynthesis
;
genetics
;
Epidermal Growth Factor
;
biosynthesis
;
genetics
;
Escherichia coli
;
genetics
;
metabolism
;
Humans
;
Immunization
;
Mice
;
Mice, Inbred C57BL
;
Molecular Sequence Data
;
Random Allocation
;
Receptor, Epidermal Growth Factor
;
antagonists & inhibitors
;
immunology
;
Recombinant Fusion Proteins
;
biosynthesis
;
genetics
;
immunology
;
Transforming Growth Factor alpha
;
biosynthesis
;
genetics
10.Construction and screening of phage antibody libraries against epidermal growth factor receptor and soluble expression of single chain Fv.
Wei-Jin SHENG ; Qing-Fang MIAO ; Yong-Su ZHEN
Acta Pharmaceutica Sinica 2009;44(6):597-602
Recent studies have shown that epidermal growth factor receptor (EGFR) is an important target for cancer therapy. The present study prepared single chain Fv (scFv) directed against EGFR. Balb/c mice were immunized by human carcinoma A431 cells, and total RNA of the splenic cells was extracted. VH and VL gene fragments were amplified by RT-PCR and further joined into scFv gene with a linker, then scFv gene fragments were ligated into the phagemid vector pCANTAB 5E. The phagemid containing scFv were transformed into electro-competent E. coli TG1 cells. The recombinant phage antibody library was constructed through rescuing the transformed cells with help phage M13K07. The specified recombinant phages were enriched through 5 rounds of affinity panning and the anti-EGFR phage scFv clones were screened and identified with ELISA. A total of 48 clones from the library were selected randomly and 45 clones were identified positive. After infecting E. coli HB2151 cells with one positive clone, soluble recombinant antibodies about 27 kD were produced and located in the periplasm and the supernatant. The result of sequencing showed that the scFv gene was 768 bp, which encoded 256 amino acid residues. VH and VL including 3 CDRs and 4 FRs, respectively, were all homologous to mouse Ig. The soluble scFv showed the specific binding activity to purified EGFR and EGFR located in carcinoma cell membrane. The successful preparation of anti-EGFR scFv will provide an EGFR targeted molecule for the development of antibody-based drugs and biological therapy of cancer.
Animals
;
Antibodies, Monoclonal
;
Cell Line, Tumor
;
Humans
;
Immunoglobulin Light Chains
;
genetics
;
immunology
;
Male
;
Mice
;
Mice, Inbred BALB C
;
Peptide Library
;
Receptor, Epidermal Growth Factor
;
genetics
;
immunology
;
Single-Chain Antibodies
;
genetics
;
immunology